BridgeBio Pharma, Inc. (BBIO)
| Market Cap | 8.53B |
| Revenue (ttm) | 21.95M |
| Net Income (ttm) | -402.20M |
| Shares Out | 118.17M |
| EPS (ttm) | -4.73 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $69.48 |
| Previous Close | $66.44 |
| Change ($) | 3.04 |
| Change (%) | 4.58% |
| Day's Open | 65.49 |
| Day's Range | 64.68 - 69.58 |
| Day's Volume | 587,804 |
| 52-Week Range | 16.11 - 71.11 |
PALO ALTO, Calif. and SAN FRANCISCO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) and Eidos Therapeutics, Inc. (“Eidos”) (Nasdaq: EIDX) today announced...
PALO ALTO, Calif. and SAN FRANCISCO, Jan. 13, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (“BridgeBio”) (Nasdaq: BBIO) and Eidos Therapeutics, Inc. (“Eidos”) (Nasdaq: EIDX) announced today...
PALO ALTO, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on Janu...
Clinical trial readouts this year could cause these closely watched biotech stocks to explode overnight.
PALO ALTO, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) today announced that leading proxy advisory firm Institutional Shareholder Services (“ISS”) recommend...
SAN FRANCISCO, Dec. 23, 2020 (GLOBE NEWSWIRE) -- UC San Francisco (UCSF) and BridgeBio Pharma, Inc. (NASDAQ: BBIO) today announced a partnership to drive the advancement of academic innovation...
According to current portfolio statistics, a Premium feature of GuruFocus, the top five health care positions in Andreas Halvorsen (Trades, Portfolio)'s equity portfolio as of the third quarte...
Contour Therapeutics Brings Together Leaders with Extensive Cardiovascular, Genetics and Drug Development Expertise
PALO ALTO, Calif., Dec. 04, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on Dece...
This company's about to begin delivering a stream of new drugs that target genetic diseases, and hardly anyone's heard about it.
WILMINGTON, Del., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating BridgeBio Pharma, Inc. (“BridgeBio”) (NASDAQ GS: BBIO) regarding possible breaches...
• Application accepted under P riority R eview designation • Application accepted into Real Time Oncology Review (RTOR) pilot program • This is BridgeBio's s econd NDA a cceptance • Applic...
SAN FRANCISCO, Nov. 13, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) and affiliate Navire Pharma, Inc. announced today that the first patient has been dosed in a Phase 1 clin...
China Grand Pharma announced a $340 million agreement to develop and commercialize Telix Pharma's molecularly-targeted radiation products in China. JW Therapeutics, a Shanghai cell therapy com...
BridgeBio Pharma (BBIO) delivered earnings and revenue surprises of -1.03% and -52.89%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the...
-Merger agreement executed between BridgeBio and Eidos Therapeutics; Potential to bring BridgeBio's clinical and commercial development infrastructure to bear upon Eidos' Acoramidis
PALO ALTO, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on Nove...
BridgeBio Pharma (BBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BOSTON, Oct. 27, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) and affiliate Phoenix Tissue Repair today announced that the first patient has been dosed in a Phase 2 study of ...
PALO ALTO, Calif. and DENVER, Oct. 21, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) and the University of Colorado Anschutz Medical Campus today announced a collaboration to ...
LA JOLLA and PALO ALTO, Calif., Oct. 21, 2020 (GLOBE NEWSWIRE) -- The Salk Institute and BridgeBio Pharma, Inc. (Nasdaq: BBIO) today announced a three-year collaboration agreement formed to ad...
New York, New York--(Newsfile Corp. - October 5, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To view an enhanced version of this graphic, please visit:https://orde...
BridgeBio Pharma Inc (NASDAQ: BBIO) said on Monday that it will increase its stake in Eidos Therapeutics Inc (NASDAQ: EIDX) by 36.3% in a cash deal that is valued at £134.95 million (aggregate...
BridgeBio Pharma Inc. BBIO, announced Monday an agreement to buy Eidos Therapeutics Inc. EIDX, -0.30% in a deal that values Eidos at about $2.83 billion. Eidos's stock is currently halted for ...
BridgeBio to Acquire All Outstanding Shares of E idos it Does Not Already Own
These underappreciated biotechnology start-ups could turn heads one day -- but not yet.
BridgeBio Pharma said the FDA accepted its New Drug Application, the first NDA for the company, for its therapy to treat a rare, at times fatal, disease that often targets infants. BBIO rose.
Application accepted under Priority Review designation with Breakthrough Therapy Designation and Rare Pediatric Disease Designation previously granted
PALO ALTO, Calif., Sept. 22, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases and cancers with clear gen...
PALO ALTO, Calif., Sept. 21, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate Calcilytix Therapeutics, Inc. announced today the initiation of a Phase 2 single-center ...
We used TipRanks analyst ranking service to pinpoint Wall Street's best-performing analysts.
-Initiated four clinical trials, progressed its additional 11 ongoing clinical trials and submitted three INDs to FDA since the beginning of 2020
$26.5 million total near-term payments to BridgeBio, plus participation in long-term value creation of up to $505 million in milestone payments, tiered double-digit royalty payments and an eq...
PHOENIX and SAN FRANCISCO, July 28, 2020 (GLOBE NEWSWIRE) -- Ivy Brain Tumor Center at Barrow Neurological Institute announced today that the first patient has been dosed in an investigato...
SAN FRANCISCO, July 15, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate QED Therapeutics announced today that the first child with achondroplasia has been dosed with...
BOSTON, July 10, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate Phoenix Tissue Repair (PTR) today announced an upcoming presentation of interim data from an ongoing...
PALO ALTO, Calif., June 24, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that it ha...
Partnership to Leverage University of Florida’s Research in Gene Therapy and BridgeBio’s Translational Expertise in Rare and Genetic Disease Partnership to Leverage University of Florida’s Res...
PALO ALTO, Calif., June 18, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (NASDAQ: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that it ha...
SAN FRANCISCO, June 11, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate ML Bio Solutions today announced that the first subject has been dosed in the Phase 1 clinica...
Stocks are firing on all cylinders again and have clawed back most of their bear-market losses.
SAN FRANCISCO, May 29, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate QED Therapeutics announced today that it will present data at the American Society of Clinical...
BOSTON, May 13, 2020 (GLOBE NEWSWIRE) -- Phoenix Tissue Repair, Inc. (PTR), an affiliate company of BridgeBio Pharma, Inc. (Nasdaq: BBIO) today announced updates to its ongoing Phase 1/2 stu...
Ended quarter with $928 million in cash, cash equivalents and marketable securities Ended quarter with $928 million in cash, cash equivalents and marketable securities
PALO ALTO, Calif., May 06, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) announced today that it will present at the Bank of America Securities 2020 Health Care Conference o...
PALO ALTO, Calif., May 05, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on May...
Corona Anchor Series: BridgeBio Is A Secure Long-Term Investment
BridgeBio (BBIO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
About BBIO
BridgeBio Pharma engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 20 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include BBP-265, an oral small molecule transthyretin (TTR), which is ongoing Phase 3 clinical trial for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhi... [Read more...]
| Industry Biotechnology | IPO Date Jun 27, 2019 |
| CEO Neil Kumar | Employees 369 |
| Stock Exchange NASDAQ | Ticker Symbol BBIO |
Analyst Forecasts
According to 8 analysts, the average rating for BBIO stock is "Buy." The 12-month stock price forecast is 63.75, which is a decrease of -8.25% from the latest price.